Navigation

Dementia: supplementary costing report and template

The clinical guideline on Dementia was accompanied by implementation tools including a costing report and template. However, it has subsequently emerged that costs could arise from a recommendation in this guideline, when viewed in conjunction with changes to the technology appraisal on drugs for people with Alzheimer's disease. This supplementary cost report estimates the impact of this recommendation. All other estimates in the costing for the clinical guideline remain valid and this supplementary cost is additional to the cost of 40.6 million estimated in the clinical guideline leading to a revised total cost of 46 million.

This page was last updated: 30 March 2010

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.

Selected, reliable information for health and social care in one place

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.